Stocks and Investing Stocks and Investing
Mon, March 8, 2021
Fri, March 5, 2021
Thu, March 4, 2021
Wed, March 3, 2021
Tue, March 2, 2021

Matthew Harrison Maintained (BLUE) at Hold with Decreased Target to $45 on, Mar 2nd, 2021


Published on 2024-10-27 15:49:39 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Maintained "bluebird bio, Inc." (BLUE) at Hold with Decreased Target from $50 to $45 on, Mar 2nd, 2021.

Matthew has made no other calls on BLUE in the last 4 months.



There are 5 other peers that have a rating on BLUE. Out of the 5 peers that are also analyzing BLUE, 2 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Cory Kasimov of "JP Morgan" Downgraded from Buy to Hold and Decreased Target to $39 on, Wednesday, February 17th, 2021
  • Matthew Luchini of "BMO Capital" Downgraded from Buy to Hold and Held Target at $56 on, Thursday, November 5th, 2020


These are the ratings of the 3 analyists that currently disagree with Matthew


  • Yun Zhong of "Berenberg" Initiated at Strong Buy and Held Target at $64 on, Wednesday, November 11th, 2020
  • Jason Gerberry of "B of A Securities" Maintained at Strong Buy with Decreased Target to $81 on, Thursday, November 5th, 2020
  • Mani Foroohar of "SVB Leerink" Maintained at Buy with Decreased Target to $99 on, Thursday, November 5th, 2020